Saturday, September 23, 2023
News Media Empire
  • About Us
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • Home
  • World News
  • Politics
  • Business & Economy
  • Money
  • Science & Tech
  • Opinion
  • Lifestyle
  • Health
  • Sports
  • Entertainment
  • Crypto
No Result
View All Result
  • Home
  • World News
  • Politics
  • Business & Economy
  • Money
  • Science & Tech
  • Opinion
  • Lifestyle
  • Health
  • Sports
  • Entertainment
  • Crypto
No Result
View All Result
News Media Empire
No Result
View All Result
Home Health

AstraZeneca COVID-19 drug prevents severe disease if given early, company says – National | Globalnews.ca

October 11, 2021
in Health
0
AstraZeneca COVID-19 drug prevents severe disease if given early, company says - National | Globalnews.ca
0
SHARES
Share on FacebookShare on TwitterShare on RedditShare on Whatsapp


AstraZeneca‘s antibody cocktail against COVID-19, which has proven to work as a preventative shot in the non-infected, was also shown to save lives and prevent severe disease when given as treatment within a week of first symptoms.

The drug, a combination of two antibodies called AZD7442, reduced the risk of severe COVID-19 or death by 50 per cent in non-hospitalized patients who have had symptoms for seven days or less, the Anglo-Swedish drugmaker said on Monday.

Get Free Advertise Coin

The risk reduction was even better in patients who started therapy within just five days of initial symptoms, but AstraZeneca joins an already crowded field of medicines that were shown to prevent deterioration in patients with mild disease when given soon after diagnosis.

Read more:
AstraZeneca seeks U.S. emergency approval for COVID-19 prevention drug

Story continues below advertisement

AstraZeneca executive Mene Pangalos said in a media call that the treatment results would mainly underscore the potential future use as a non-vaccine prevention.

“If and when this is approved it will be used in the treatment setting as well. But the real differentiator for this antibody is going to be in the prophylactic setting,” he said.

Similar therapies made with a class of drugs called monoclonal antibodies are being developed by Regeneron, Eli Lilly and GlaxoSmithKline with partner Vir. These therapies are approved for emergency use in the United States for treating mild-to-moderate COVID-19.

Regeneron’s therapy showed 72 per cent protection against symptomatic infection in the first week, and 93 per cent after that.


Click to play video: 'Fauci says Merck data on its COVID-19 pill treatment ‘impressive’'






1:06
Fauci says Merck data on its COVID-19 pill treatment ‘impressive’


Fauci says Merck data on its COVID-19 pill treatment ‘impressive’ – Oct 1, 2021

GSK-Vir’s showed a 79 per cent reduction in the risk of hospitalization or death due to any cause, while Eli Lilly’s therapy showed a 70 per cent reduction in viral load at day seven compared to a placebo.

Story continues below advertisement

Merck & Co Inc, in turn, is emphasizing the convenience of use of its anti-COVID-19 tablet, which cut the risk of having to got to hospital or of dying by 50 per cent in a trial of early-stage patients who had at least one risk factor.

Merck, collaborating with Ridgeback Biotherapeutics, on Monday applied for U.S. emergency clearance for the oral drug.

AstraZeneca, whose COVID-19 vaccine has been widely used across the globe, asked U.S. regulators last week to grant emergency use authorization for AZD7442 as a preventative shot.

Read more:
Merck asks U.S. FDA for emergency stamp for COVID-19 tablet

As such, it is designed to protect people who do not have a strong enough immune response to vaccines, primarily those who have received organ transplants or who are in cancer care.

If full market clearance is obtained after any emergency approval the market could widen, for instance, to include crew and passengers of a cruise ship, said Pangalos.

“You can say the same for people who don’t want to be vaccinated but want an antibody,” he added.

AstraZeneca said it is submitting the new treatment data on AZD7442 to global health regulators.

Story continues below advertisement

Read more:
Regeneron’s antibody COVID-19 treatment is popular in the U.S. — why not in Canada?

The trial took place across 13 countries and involved more than 900 adult participants, 90 per cent of whom suffered from conditions that made the particularly vulnerable to COVID-19, such as cancer and diabetes. One half receiving AZD7442 and the rest a placebo.

Full trial results will be submitted for publication in a peer-reviewed journal, AstraZeneca said.

AZD7442 contains laboratory-made antibodies designed to linger in the body for months to contain the virus in case of an infection. A vaccine, in contrast, relies on an intact immune system to develop targeted antibodies and infection-fighting cells.

While Monday’s results cover the use of AZD7442 in non-hospitalized patients, a separate trial is also studying its use as a treatment for hospitalized COVID-19 patients.

(Reporting by Ludwig Burger in Frankfurt, Yadarisa Shabong in Bengaluru; Editing by Saumyadeb Chakrabarty, Kirsten Donovan and Alexander Smith)


View link »









Source link

Tags: AstraZenecaastrazeneca covidAstraZeneca COVID-19AstraZeneca FDAAstraZeneca treatmentsCOVIDCovid treatmentscovid-19COVID-19 AntibodiesCOVID-19 illnessCOVID-19 TreatmentsHealthtreatments for covidWorld
Previous Post

Fossil discovery reveals new species in 16-million-year-old amber

Next Post

Ukrainian airline ditches skirts and heels for loose suits and sneakers

Related Posts

New COVID shot provides ‘boost in protection’ against new variants: doctors - National | Globalnews.ca
Health

New COVID shot provides ‘boost in protection’ against new variants: doctors – National | Globalnews.ca

September 22, 2023
Rehab programs can improve quality of life for patients struggling with long COVID: research | CBC News
Health

Rehab programs can improve quality of life for patients struggling with long COVID: research | CBC News

September 22, 2023
U.S. to produce more COVID-19 tests for free distribution as cases rise - National | Globalnews.ca
Health

U.S. to produce more COVID-19 tests for free distribution as cases rise – National | Globalnews.ca

September 22, 2023
Next Post
Ukrainian airline ditches skirts and heels for loose suits and sneakers

Ukrainian airline ditches skirts and heels for loose suits and sneakers

Pearl Thusi, Robert Marawa

Robert Marawa on Pearl Thusi breakup: 'There's always been mutual respect' | Channel

Jordaan confirmed that Safa would meet with Health Minister Joe Phaahla tomorrow to seek clarity on the proposed move to have fans in FNB Stadium next week. Photo: Gallo images

Bafana game to be used as pilot project for fan return, says Safa's Ngwenya | Sport

Discussion about this post

AdvertiseCoin ADCO Get Now Free
News Media Empire

Newsmediaempire is an online news source that provides the latest news and other information about everything that you must need to know. It publishes news related to various fields like world, business, sports, politics, tech, health, lifestyle, and other different exclusive stories.

Let's connect!

Categories

  • Business & Economy
  • Crypto
  • Entertainment
  • Health
  • Lifestyle
  • Money
  • Opinion
  • Politics
  • Science & Tech
  • Sports
  • World News

Recent News

  • Inside the M&S Beauty Advent Calendar for 2023, including our Beauty Editor’s favourite products September 23, 2023
  • Return to downtown is important as fall arrives, ships depart | Op-Ed September 22, 2023
  • Dry laundry indoors ‘fast’ without a tumble dryer and avoid ‘nasty smells’ September 22, 2023

Join Our Newsletter!

    • About Us
    • Contact
    • Privacy Policy
    • Terms & Conditions

    newsmediaempire.com © 2021 All rights reserved.

    No Result
    View All Result
    • About Us
    • Contact
    • Home 1
    • Home 2
    • Home 3
    • Privacy Policy
    • Random
    • Sample Page
    • Terms & Conditions

    newsmediaempire.com © 2021 All rights reserved.

    en English
    ar Arabicbg Bulgarianzh-CN Chinese (Simplified)nl Dutchen Englishfr Frenchde Germanit Italianpt Portugueseru Russianes Spanish
    This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.